Hudson Bay Capital Management
URGN icon

Hudson Bay Capital Management’s UroGen Pharma URGN Stock Holding History

Hudson Bay Capital Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-410,607
Closed -$3.94M – 1657
2025
Q1 		$4.54M Buy
410,607
+177,285
+76% +$1.89M 0.01% 619
2024
Q4 		$2.48M Buy
+233,322
New +$2.79M 0.01% 623

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Hudson Bay Capital Management's URGN Position: Q2 2025 in Review

Hudson Bay Capital Management sold out of UroGen Pharma (URGN) in Q2 2025, closing a stake of 410,607 shares — an estimated $3.94M sold.

Hudson Bay Capital Management first reported a position in URGN in Q4 2024 and held it in 2 quarters. The position peaked at $4.54M in Q1 2025. 150 funds tracked by Wall St. Rank hold URGN as of Q2 2025.

  • Hudson Bay Capital Management reported no remaining UroGen Pharma position as of Q2 2025 after selling out during the quarter.
  • Hudson Bay Capital Management sold 410,607 UroGen Pharma shares in Q2 2025, an estimated $3.94M.
  • Hudson Bay Capital Management first reported a position in UroGen Pharma in Q4 2024 and held it in 2 quarters.
  • Hudson Bay Capital Management's UroGen Pharma position peaked at $4.54M in Q1 2025.
  • 150 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2025.

Based on Hudson Bay Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.